{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:13Z","timestamp":1790727013215,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002635","name":"Inha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.seizure.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T23:30:20Z","timestamp":1455147020000},"page":"8-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Eun-Kee","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongtae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsup","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keon-Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongseong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2016.02.002_bib0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2016.02.002_bib0130","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1111\/j.1528-1157.2000.tb02175.x","article-title":"Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults","volume":"41","author":"Reife","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.02.002_bib0135","series-title":"The epilepsy prescriber's guide to antiepileptic drugs","author":"Philip","year":"2014"},{"key":"10.1016\/j.seizure.2016.02.002_bib0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.seizure.2016.02.002_bib0145","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","article-title":"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment","volume":"108","author":"Manitpisitkul","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2016.02.002_bib0150","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2016.02.002_bib0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2016.02.002_bib0160","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1248\/bpb.33.1176","article-title":"A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy","volume":"33","author":"Vovk","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.seizure.2016.02.002_bib0165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.seizure.2016.02.002_bib0170","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinthera.2005.05.001","article-title":"Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy","volume":"27","author":"Carlsson","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.seizure.2016.02.002_bib0175","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejps.2013.07.008","article-title":"Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling","volume":"50","author":"Jovanovic","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.seizure.2016.02.002_bib0180","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.0013-9580.2005.55204.x","article-title":"Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine","volume":"46","author":"Britzi","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.02.002_bib0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.eplepsyres.2010.12.004","article-title":"Topiramate pharmacokinetics in infants and young children: contribution of population analysis","volume":"93","author":"Bouillon-Pichault","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2016.02.002_bib0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.seizure.2016.02.002_bib0195","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2016.02.002_bib0200","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1528-1167.2007.01201.x","article-title":"Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy","volume":"48","author":"Otoul","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.02.002_bib0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e31827efe1d","article-title":"Factors influencing serum topiramate concentrations in routine therapeutic drug monitoring in Korean adult patients with epilepsy","volume":"35","author":"Huh","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2016.02.002_bib0210","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","article-title":"Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2016.02.002_bib0215","first-page":"S18","article-title":"Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs","volume":"38","author":"Johannessen","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.02.002_bib0220","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1528-1167.2012.03532.x","article-title":"Topiramate increases the risk of valproic acid-induced encephalopathy","volume":"54","author":"Noh","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.02.002_bib0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1528-1157.2002.42401.x","article-title":"Topiramate enhances the risk of valproate-associated side effects in three children","volume":"43","author":"Longin","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.02.002_bib0230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.seizure.2016.02.002_bib0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-200406000-00005","article-title":"Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications","volume":"26","author":"Adin","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2016.02.002_bib0240","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131116000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131116000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:46:43Z","timestamp":1761011203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131116000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":24,"alternative-id":["S1059131116000443"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2016.02.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2016.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}